The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to ...

By Christy Santhosh June 26 (Reuters) - Europe's drug regulator on Friday recommended revoking the marketing authorization ...

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate ...

Amgen (AMGN) stock is in focus as an expert panel of the European Medicines Agency recommends withdrawal of the company's ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) ...

Amgen is rated between Hold and Buy with shares potentially slightly undervalued or fairly valued depending on FCF ...

The tablets involved in the recall were distributed in the U.S. from Oct. 28, 2021, to Dec. 30, 2025 ...

The European Medicines Agency recommended that CSL Ltd.’s drug Tavneos be pulled from the market after finding it was ...

Amgen’s up-to-$2.5 billion acquisition of the antibody specialist Teneobio is costing the California drugmaker once again. | ...

Once the CHMP has delivered marketing authorization recommendations, final sign-off on the decisions must still be conferred ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.